Skip to main content
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. — Investor Relations & Filings

Ticker · NERV ISIN · US6033802058 LEI · 54930017PANCHC5LYH79 US Manufacturing
Open in API
Filings indexed 589 across all filing types
Latest filing 2015-05-19 Board/Management Inform…
Country US United States of America
Listing US NERV

About Minerva Neurosciences, Inc.

https://www.minervaneurosciences.com/

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of product candidates for the treatment of central nervous system (CNS) diseases. The company's lead product candidate is roluperidone, which is being developed to treat the negative symptoms of schizophrenia. Minerva Neurosciences leverages its expertise in clinical development to design innovative trials with clinical endpoints aimed at demonstrating direct patient benefit.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 18, 2015, reporting the appointment and election of a new board member, Dr. Fouzia Laghrissi-Thode. The content focuses on changes in the company's board of directors and committee assignments. There is no financial data or report attached, only a press release as an exhibit. The key section is Item 5.02, which pertains to departure or election of directors or officers. This matches the category for Board/Management Information (MANG).
2015-05-19 English
FORM 3 SUBMISSION
Director's Dealing
2015-05-18 English
PROSPECTUS
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(4) related to the resale of shares by selling stockholders. It details the offering of common stock, use of proceeds, risk factors, and other information typical of a securities offering document. It is not a financial report, earnings release, or management discussion. It is a disclosure document related to capital raising and share resale. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus, not just an announcement or brief notice.
2015-05-12 English
Regulatory Filings 2015
Regulatory Filings
2015-05-12 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A Registration Statement Amendment No. 1 filed with the SEC, dated May 7, 2015, for Minerva Neurosciences, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes details about the securities being registered, the selling stockholders, use of proceeds, risk factors, and other offering-related information. This type of filing is a capital markets document related to fundraising and securities issuance, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or certification, so it is not RPA or RNS. Confidence is high given the clear identification as an SEC S-1/A registration statement amendment related to securities offering.
2015-05-07 English
10-Q
Interim / Quarterly Report Q1 2015
2015-05-07 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.